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Purpose: to analyze treatment outcome following Single-Dose 
Image-Guided Radiotherapy (SDRT) using PERCIST criteria 
based on 18-F-fluoro-2-deoxy-D-glucose PET Standardized 
Uptake Value (SUVmax) assessments in patients with limited 
extra-cranial metastatic disease. 
Methods and Materials: 259 lesions in 101 consecutive 
patients with early metastatic disease with less than five 
lesions at initial presentation (mean 2.1, range 1-5 lesions) 
were treated between November 2011 and March 2015 with 
SDRT. Mean and median PTV volume were 40.6 and 18.1 cm3 
(range, 1.3-339), respectively. PTV prescription dose was 
24Gy. Of the 101 patients, 56 (55%) of had a solitary 
metastasis at the time of first treatment. While the majority 
of the patients received only one treatment, 27% (27/101) 
received additional treatments (mean 1.4, median 1 range, 
1-7) for relapses elsewhere. Thus, the mean number of 
lesions for the entire population was 2.6 (range, 1-13). 
SUVmax were acquired at the time of FDG-PET/CT planning 
before SDRT, at 3 and 6 months post-treatment and every 6 
months thereafter. Treatment outcome was assessed by 
PERCIST criteria, with metabolic relapse defined as any 
increase of SUVmax >20% above nadir level. All metabolic 
relapses were confirmed by morphologic imaging. Lesions had 
a minimum of 2 post-treatment scans (mean 4; range 2-11) 
with a minimum follow-up of 6 months.  
Results: actuarial 2- and 3-year overall survival for this 
cohort were 71% and 64%, respectively.  At a median follow-
up of 16.1 months (range, 6.7- 43.5 months), 6% (15/259) of 
lesions developed PERCIST failure within the irradiated 
region yielding a 3-year actuarial freedom of local relapse of 
90%. Mean time to local relapse was 9 months. All 
recurrences occurred within the first 19 months. The mean 
percentage increase in SUVmax in relapsing lesions was 429% 
(range, 28% - 2530%). The mean and median baseline SUVmax 
were 8.9 and 6.9, respectively (range, 0.7-52.0). At 3 months 
post-SDRT, 15% (40/259) of the lesions had a >90% reduction 
in SUVmax (PERCIST complete metabolic response). SUVmax 
declines >75% (ΔSUVmax >75%) was significantly associated with 
freedom from metabolic relapse at 3 years (p = 0.02). Lesions 
with with ΔSUVmax >75% had 94% local control at 36 months vs. 
77% for ΔSUVmax ≤75%. On univariate analysis, no correlation 
was found with primary tumor histology, metastasis site, PTV 
volume or ongoing systemic treatment and the likelihood of 
local relapse free survival. 
Conclusion: These results confirm that high dose SDRT 
provides long-term local relapse-free survival using objective 
PERCIST therapeutic response criteria in patients with early 
metastatic disease. Additionally, they provide preliminary 
evidence that an early evaluation in metabolic changes post-
SDRT may serve as a useful prognostic tool in the assessment 
of lesions treated with ablative intent.  
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Purpose: Among the large number of radionuclides of medical 
interest, Sc-44 is promising for PET imaging. Either the Sc-
44g or the Sc-44m can be used for such applications, 
depending on the molecule used as vector. This study 
compares the production rates of both Sc-44 states, when 
protons or deuterons are used as projectiles on an enriched 
calcium-44 target for 3 scenarios: the production of Sc-44g 
for conventional PET imaging, its production for the new 3 γ 
imaging technique developed at the SUBATECH laboratory 
and the production of Sc-44m to be used as Sc-44m/Sc-44g in 
vivo generator for antibody labelling. 
Materials/methods: Experimental production cross section 
have been measured up to 34 MeV for the Ca-44(d,2n)Sc-
44m,Sc-44g reactions, using the stacked-foil technique [1] 
and gamma-spectrometry, at the ARRONAX cyclotron [2]. The 
stacks were made of Ca-44CO3 as targets and aluminum foils 
as degraders. Monitor foils were made of natural titanium in 
order to use the IAEA recommended cross section of the Ti-
nat(d,x)V-48 reaction. Some results on the production of K-
42,43 and Sc-43 have also been obtained but not in all the 
targets as the main objective was first to properly measure 
the activity of Sc-44m and Sc-44g. The results are compared 
with the TALYS code [3] version 1.6. Based on these 
experimental data, the Thick-Target production Yields (TTY) 
of Sc-44m and Sc-44g are calculated and compared with 
those for the proton route for the 3 scenarios [4]. 
Results: Experimental cross section values have been 
obtained for the first time for Ca-44(d,2n)Sc-44m,Sc-44g 
reactions with some information on Sc-43 and K-42,43 also 
produced during the irradiation. The TALYS results are close 
to the experimental values for the Ca-44(p,n) and Ca-
44(d,2n) reactions whereas it is not able to reproduce the 
data for the production of potassium isotopes. Our new 
experimental results have shown that the Sc-44m/Sc-44g 
cross section and TTY ratios are higher with deuterons than 
with protons, whatever the incident beam energy. 
Conclusions: This study shows that the use of a proton beam 
is the best choice, as compared to deuterons, to produce Sc-
44g for PET imaging using peptides or small molecules with 
rapid distribution in the body. For the 3 γ imaging technique, 
Sc-44g has to be produced with protons of 15 MeV to limit the 
background generated by Sc-44m and Sc-43 decay. The 
production of the Sc-44m to be used as Sc-44m/Sc-44g in vivo 
generator for antibody labelling required the highest Sc-44m 
production rate, with a limited amount of Sc-44g directly 
produced. The production of Sc-44m is advantageous with 
deuterons as projectiles, using a calcium-44 carbonate 
target. Sc-44m can be produced with a 15 MeV deuteron. A 
higher amount of Sc-44m is produced with a 30 MeV deuteron 
beam and some cooling time, before the extraction and 
separation processes, allows to significantly reduce the 
contribution of directly produced Sc-44g and Sc-43. 
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